Abeona Therapeutics Sells Priority Review Voucher for $155M, Boosts Financial Position

Abeona Therapeutics sold its Rare Pediatric Disease Priority Review Voucher for $155 million, boosting its financial position to approximately $225 million in cash resources. The sale ensures over two years of operating capital and supports the company's growth plans, including the anticipated first treatment with ZEVASKYN in Q3 2025 and projected profitability by early 2026.